The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 ...

TOKYO -- Japanese pharmaceutical companies including Daiichi Sankyo and Fujifilm Holdings are increasing efforts to develop biopharmaceutical talent, aiming for 50% to 100% growth in such experts as ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

IHH Healthcare Berhad strengthens India presence through collaboration between Fortis Healthcare and Gleneagles Healthcare India for growth.

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd.

Daiichi Sankyo and MSD's partnership, which began in October 2023, encompasses the co-development and commercialisation of patritumab deruxtecan (HER3-DXd), raludotatug deruxtecan (R-DXd), and I-DXd.

On top of being Enhertu’s first foray into DTC marketing, the campaign represents “the first DTC that we’ve developed at Daiichi Sankyo for any of our oncology products," Dan Switzer, head ...

Laura McMullin, General Manager, Daiichi Sankyo UK, has been appointed Vice President of the ABPI to support UK life sciences ...